Navidea biopharmaceuticals reports fourth quarter 2021 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and year-to-date for the period ended december 31, 2021. alexander l. cappello, chair of navidea's board of directors, said, “we remain focused on our mission of developing precision immunodiagnostic agents and immunotherape
NAVB Ratings Summary
NAVB Quant Ranking